During the study period, no participants were enrolled in the study despite extensive recruitment methods.

The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age

Inclusion Criteria:

• Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment

Exclusion Criteria:

• Women whose ipilimumab exposure is outside the window of pregnancy exposure
• Pregnancies for which there is only paternal exposure to Yervoy

Other protocol defined inclusion/exclusion criteria could apply

Primary Care Clinic